id stringlengths 13 16 | sentence stringlengths 46 809 | label stringclasses 6
values |
|---|---|---|
11716850.T29.T50 | In this study, we examined the effects of mitiglinide on various cloned <C>K</C>(ATP) channels (<P>Kir6.2</P>/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide. | 0 |
11716850.T29.T51 | In this study, we examined the effects of mitiglinide on various cloned <C>K</C>(ATP) channels (Kir6.2/<P>SUR1</P>, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide. | 0 |
11716850.T29.T52 | In this study, we examined the effects of mitiglinide on various cloned <C>K</C>(ATP) channels (Kir6.2/SUR1, <P>Kir6.2</P>/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide. | 0 |
11716850.T29.T53 | In this study, we examined the effects of mitiglinide on various cloned <C>K</C>(ATP) channels (Kir6.2/SUR1, Kir6.2/<P>SUR2A</P>, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide. | 0 |
11716850.T29.T54 | In this study, we examined the effects of mitiglinide on various cloned <C>K</C>(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and <P>Kir6.2</P>/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide. | 0 |
11716850.T29.T55 | In this study, we examined the effects of mitiglinide on various cloned <C>K</C>(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/<P>SUR2B</P>) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide. | 0 |
11716850.T30.T50 | In this study, we examined the effects of mitiglinide on various cloned K(<C>ATP</C>) channels (<P>Kir6.2</P>/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide. | 0 |
11716850.T30.T51 | In this study, we examined the effects of mitiglinide on various cloned K(<C>ATP</C>) channels (Kir6.2/<P>SUR1</P>, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide. | 0 |
11716850.T30.T52 | In this study, we examined the effects of mitiglinide on various cloned K(<C>ATP</C>) channels (Kir6.2/SUR1, <P>Kir6.2</P>/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide. | 0 |
11716850.T30.T53 | In this study, we examined the effects of mitiglinide on various cloned K(<C>ATP</C>) channels (Kir6.2/SUR1, Kir6.2/<P>SUR2A</P>, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide. | 0 |
11716850.T30.T54 | In this study, we examined the effects of mitiglinide on various cloned K(<C>ATP</C>) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and <P>Kir6.2</P>/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide. | 0 |
11716850.T30.T55 | In this study, we examined the effects of mitiglinide on various cloned K(<C>ATP</C>) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/<P>SUR2B</P>) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, nateglinide. | 0 |
11716850.T49.T31 | In this study, we examined the effects of mitiglinide on various cloned <P>K(ATP) channels</P> (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another <C>meglitinide</C>-related compound, nateglinide. | 0 |
11716850.T50.T31 | In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (<P>Kir6.2</P>/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another <C>meglitinide</C>-related compound, nateglinide. | 0 |
11716850.T51.T31 | In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/<P>SUR1</P>, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another <C>meglitinide</C>-related compound, nateglinide. | 0 |
11716850.T52.T31 | In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, <P>Kir6.2</P>/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another <C>meglitinide</C>-related compound, nateglinide. | 0 |
11716850.T53.T31 | In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/<P>SUR2A</P>, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another <C>meglitinide</C>-related compound, nateglinide. | 0 |
11716850.T54.T31 | In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and <P>Kir6.2</P>/SUR2B) reconstituted in COS-1 cells, and compared them to another <C>meglitinide</C>-related compound, nateglinide. | 0 |
11716850.T55.T31 | In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/<P>SUR2B</P>) reconstituted in COS-1 cells, and compared them to another <C>meglitinide</C>-related compound, nateglinide. | 0 |
11716850.T49.T32 | In this study, we examined the effects of mitiglinide on various cloned <P>K(ATP) channels</P> (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, <C>nateglinide</C>. | 0 |
11716850.T50.T32 | In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (<P>Kir6.2</P>/SUR1, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, <C>nateglinide</C>. | 0 |
11716850.T51.T32 | In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/<P>SUR1</P>, Kir6.2/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, <C>nateglinide</C>. | 0 |
11716850.T52.T32 | In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, <P>Kir6.2</P>/SUR2A, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, <C>nateglinide</C>. | 0 |
11716850.T53.T32 | In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/<P>SUR2A</P>, and Kir6.2/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, <C>nateglinide</C>. | 0 |
11716850.T54.T32 | In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and <P>Kir6.2</P>/SUR2B) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, <C>nateglinide</C>. | 0 |
11716850.T55.T32 | In this study, we examined the effects of mitiglinide on various cloned K(ATP) channels (Kir6.2/SUR1, Kir6.2/SUR2A, and Kir6.2/<P>SUR2B</P>) reconstituted in COS-1 cells, and compared them to another meglitinide-related compound, <C>nateglinide</C>. | 0 |
11716850.T33.T56 | Patch-clamp analysis using inside-out recording configuration showed that <C>mitiglinide</C> inhibits the <P>Kir6.2</P>/SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 microM). | CPR:4 |
11716850.T33.T57 | Patch-clamp analysis using inside-out recording configuration showed that <C>mitiglinide</C> inhibits the Kir6.2/<P>SUR1</P> channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 microM). | CPR:4 |
11716850.T33.T58 | Patch-clamp analysis using inside-out recording configuration showed that <C>mitiglinide</C> inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either <P>Kir6.2</P>/SUR2A or Kir6.2/SUR2B channel currents even at high doses (more than 10 microM). | 0 |
11716850.T33.T59 | Patch-clamp analysis using inside-out recording configuration showed that <C>mitiglinide</C> inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2/<P>SUR2A</P> or Kir6.2/SUR2B channel currents even at high doses (more than 10 microM). | 0 |
11716850.T33.T60 | Patch-clamp analysis using inside-out recording configuration showed that <C>mitiglinide</C> inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or <P>Kir6.2</P>/SUR2B channel currents even at high doses (more than 10 microM). | 0 |
11716850.T33.T61 | Patch-clamp analysis using inside-out recording configuration showed that <C>mitiglinide</C> inhibits the Kir6.2/SUR1 channel currents in a dose-dependent manner (IC50 value, 100 nM) but does not significantly inhibit either Kir6.2/SUR2A or Kir6.2/<P>SUR2B</P> channel currents even at high doses (more than 10 microM). | 0 |
11716850.T34.T63 | <C>Nateglinide</C> inhibits <P>Kir6.2</P>/SUR1 and Kir6.2/SUR2B channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM). | CPR:4 |
11716850.T34.T64 | <C>Nateglinide</C> inhibits Kir6.2/<P>SUR1</P> and Kir6.2/SUR2B channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM). | CPR:4 |
11716850.T34.T65 | <C>Nateglinide</C> inhibits Kir6.2/SUR1 and <P>Kir6.2</P>/SUR2B channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM). | CPR:4 |
11716850.T34.T66 | <C>Nateglinide</C> inhibits Kir6.2/SUR1 and Kir6.2/<P>SUR2B</P> channels at 100 nM, and inhibits Kir6.2/SUR2A channels at high concentrations (1 microM). | CPR:4 |
11716850.T34.T67 | <C>Nateglinide</C> inhibits Kir6.2/SUR1 and Kir6.2/SUR2B channels at 100 nM, and inhibits <P>Kir6.2</P>/SUR2A channels at high concentrations (1 microM). | CPR:4 |
11716850.T34.T68 | <C>Nateglinide</C> inhibits Kir6.2/SUR1 and Kir6.2/SUR2B channels at 100 nM, and inhibits Kir6.2/<P>SUR2A</P> channels at high concentrations (1 microM). | CPR:4 |
11716850.T2.T43 | Binding experiments on mitiglinide, nateglinide, and repaglinide to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of <C>[3H]glibenclamide</C> to <P>SUR1</P> (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding s... | 0 |
11716850.T69.T2 | Binding experiments on mitiglinide, nateglinide, and repaglinide to <P>SUR1</P> expressed in COS-1 cells revealed that they inhibit the binding of <C>[3H]glibenclamide</C> to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding s... | 0 |
11716850.T43.T4 | Binding experiments on mitiglinide, nateglinide, and repaglinide to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to <P>SUR1</P> (IC50 values: <C>mitiglinide</C>, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding s... | 0 |
11716850.T69.T4 | Binding experiments on mitiglinide, nateglinide, and repaglinide to <P>SUR1</P> expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: <C>mitiglinide</C>, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding s... | 0 |
11716850.T43.T5 | Binding experiments on mitiglinide, nateglinide, and repaglinide to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to <P>SUR1</P> (IC50 values: mitiglinide, 280 nM; <C>nateglinide</C>, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding s... | 0 |
11716850.T69.T5 | Binding experiments on mitiglinide, nateglinide, and repaglinide to <P>SUR1</P> expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: mitiglinide, 280 nM; <C>nateglinide</C>, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding s... | 0 |
11716850.T43.T6 | Binding experiments on mitiglinide, nateglinide, and repaglinide to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to <P>SUR1</P> (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; <C>repaglinide</C>, 1.6 microM), suggesting that they all share a glibenclamide binding s... | 0 |
11716850.T69.T6 | Binding experiments on mitiglinide, nateglinide, and repaglinide to <P>SUR1</P> expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; <C>repaglinide</C>, 1.6 microM), suggesting that they all share a glibenclamide binding s... | 0 |
11716850.T43.T7 | Binding experiments on mitiglinide, nateglinide, and repaglinide to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to <P>SUR1</P> (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a <C>glibenclamide</C> binding s... | 0 |
11716850.T69.T7 | Binding experiments on mitiglinide, nateglinide, and repaglinide to <P>SUR1</P> expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a <C>glibenclamide</C> binding s... | 0 |
11716850.T35.T43 | Binding experiments on <C>mitiglinide</C>, nateglinide, and repaglinide to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to <P>SUR1</P> (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding s... | 0 |
11716850.T35.T69 | Binding experiments on <C>mitiglinide</C>, nateglinide, and repaglinide to <P>SUR1</P> expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding s... | 0 |
11716850.T36.T43 | Binding experiments on mitiglinide, <C>nateglinide</C>, and repaglinide to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to <P>SUR1</P> (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding s... | 0 |
11716850.T36.T69 | Binding experiments on mitiglinide, <C>nateglinide</C>, and repaglinide to <P>SUR1</P> expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding s... | 0 |
11716850.T37.T43 | Binding experiments on mitiglinide, nateglinide, and <C>repaglinide</C> to SUR1 expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to <P>SUR1</P> (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding s... | 0 |
11716850.T37.T69 | Binding experiments on mitiglinide, nateglinide, and <C>repaglinide</C> to <P>SUR1</P> expressed in COS-1 cells revealed that they inhibit the binding of [3H]glibenclamide to SUR1 (IC50 values: mitiglinide, 280 nM; nateglinide, 8 microM; repaglinide, 1.6 microM), suggesting that they all share a glibenclamide binding s... | 0 |
11716850.T44.T10 | The <P>insulin</P> responses to <C>glucose</C>, mitiglinide, tolbutamide, and glibenclamide in MIN6 cells after chronic mitiglinide, nateglinide, or repaglinide treatment were comparable to those after chronic tolbutamide and glibenclamide treatment. | 0 |
11716850.T44.T11 | The <P>insulin</P> responses to glucose, <C>mitiglinide</C>, tolbutamide, and glibenclamide in MIN6 cells after chronic mitiglinide, nateglinide, or repaglinide treatment were comparable to those after chronic tolbutamide and glibenclamide treatment. | 0 |
11716850.T44.T13 | The <P>insulin</P> responses to glucose, mitiglinide, <C>tolbutamide</C>, and glibenclamide in MIN6 cells after chronic mitiglinide, nateglinide, or repaglinide treatment were comparable to those after chronic tolbutamide and glibenclamide treatment. | 0 |
11716850.T44.T14 | The <P>insulin</P> responses to glucose, mitiglinide, tolbutamide, and <C>glibenclamide</C> in MIN6 cells after chronic mitiglinide, nateglinide, or repaglinide treatment were comparable to those after chronic tolbutamide and glibenclamide treatment. | 0 |
11716850.T44.T16 | The <P>insulin</P> responses to glucose, mitiglinide, tolbutamide, and glibenclamide in MIN6 cells after chronic <C>mitiglinide</C>, nateglinide, or repaglinide treatment were comparable to those after chronic tolbutamide and glibenclamide treatment. | 0 |
11716850.T44.T17 | The <P>insulin</P> responses to glucose, mitiglinide, tolbutamide, and glibenclamide in MIN6 cells after chronic mitiglinide, <C>nateglinide</C>, or repaglinide treatment were comparable to those after chronic tolbutamide and glibenclamide treatment. | 0 |
11716850.T44.T18 | The <P>insulin</P> responses to glucose, mitiglinide, tolbutamide, and glibenclamide in MIN6 cells after chronic mitiglinide, nateglinide, or <C>repaglinide</C> treatment were comparable to those after chronic tolbutamide and glibenclamide treatment. | 0 |
11716850.T44.T19 | The <P>insulin</P> responses to glucose, mitiglinide, tolbutamide, and glibenclamide in MIN6 cells after chronic mitiglinide, nateglinide, or repaglinide treatment were comparable to those after chronic <C>tolbutamide</C> and glibenclamide treatment. | 0 |
11716850.T44.T20 | The <P>insulin</P> responses to glucose, mitiglinide, tolbutamide, and glibenclamide in MIN6 cells after chronic mitiglinide, nateglinide, or repaglinide treatment were comparable to those after chronic tolbutamide and <C>glibenclamide</C> treatment. | 0 |
11716850.T21.T45 | These results indicate that, similar to the <C>sulfonylureas</C>, mitiglinide is highly specific to the <P>Kir6.2</P>/SUR1 complex, i.e., the pancreatic beta-cell K(ATP) channel, and suggest that mitiglinide may be a clinically useful anti-diabetic drug. | 0 |
11716850.T21.T46 | These results indicate that, similar to the <C>sulfonylureas</C>, mitiglinide is highly specific to the Kir6.2/<P>SUR1</P> complex, i.e., the pancreatic beta-cell K(ATP) channel, and suggest that mitiglinide may be a clinically useful anti-diabetic drug. | 0 |
11716850.T21.T47 | These results indicate that, similar to the <C>sulfonylureas</C>, mitiglinide is highly specific to the Kir6.2/SUR1 complex, i.e., the pancreatic beta-cell <P>K(ATP) channel</P>, and suggest that mitiglinide may be a clinically useful anti-diabetic drug. | 0 |
11716850.T22.T45 | These results indicate that, similar to the sulfonylureas, <C>mitiglinide</C> is highly specific to the <P>Kir6.2</P>/SUR1 complex, i.e., the pancreatic beta-cell K(ATP) channel, and suggest that mitiglinide may be a clinically useful anti-diabetic drug. | 0 |
11716850.T22.T46 | These results indicate that, similar to the sulfonylureas, <C>mitiglinide</C> is highly specific to the Kir6.2/<P>SUR1</P> complex, i.e., the pancreatic beta-cell K(ATP) channel, and suggest that mitiglinide may be a clinically useful anti-diabetic drug. | 0 |
11716850.T22.T47 | These results indicate that, similar to the sulfonylureas, <C>mitiglinide</C> is highly specific to the Kir6.2/SUR1 complex, i.e., the pancreatic beta-cell <P>K(ATP) channel</P>, and suggest that mitiglinide may be a clinically useful anti-diabetic drug. | 0 |
11716850.T45.T23 | These results indicate that, similar to the sulfonylureas, mitiglinide is highly specific to the <P>Kir6.2</P>/SUR1 complex, i.e., the pancreatic beta-cell <C>K</C>(ATP) channel, and suggest that mitiglinide may be a clinically useful anti-diabetic drug. | 0 |
11716850.T46.T23 | These results indicate that, similar to the sulfonylureas, mitiglinide is highly specific to the Kir6.2/<P>SUR1</P> complex, i.e., the pancreatic beta-cell <C>K</C>(ATP) channel, and suggest that mitiglinide may be a clinically useful anti-diabetic drug. | 0 |
11716850.T45.T24 | These results indicate that, similar to the sulfonylureas, mitiglinide is highly specific to the <P>Kir6.2</P>/SUR1 complex, i.e., the pancreatic beta-cell K(<C>ATP</C>) channel, and suggest that mitiglinide may be a clinically useful anti-diabetic drug. | 0 |
11716850.T46.T24 | These results indicate that, similar to the sulfonylureas, mitiglinide is highly specific to the Kir6.2/<P>SUR1</P> complex, i.e., the pancreatic beta-cell K(<C>ATP</C>) channel, and suggest that mitiglinide may be a clinically useful anti-diabetic drug. | 0 |
11716850.T45.T25 | These results indicate that, similar to the sulfonylureas, mitiglinide is highly specific to the <P>Kir6.2</P>/SUR1 complex, i.e., the pancreatic beta-cell K(ATP) channel, and suggest that <C>mitiglinide</C> may be a clinically useful anti-diabetic drug. | 0 |
11716850.T46.T25 | These results indicate that, similar to the sulfonylureas, mitiglinide is highly specific to the Kir6.2/<P>SUR1</P> complex, i.e., the pancreatic beta-cell K(ATP) channel, and suggest that <C>mitiglinide</C> may be a clinically useful anti-diabetic drug. | 0 |
11716850.T47.T25 | These results indicate that, similar to the sulfonylureas, mitiglinide is highly specific to the Kir6.2/SUR1 complex, i.e., the pancreatic beta-cell <P>K(ATP) channel</P>, and suggest that <C>mitiglinide</C> may be a clinically useful anti-diabetic drug. | CPR:5 |
23487168.T14.T1 | Although generally highly specific for <P>angiotensin II type 1 receptors</P>, some ARBs, particularly <C>telmisartan</C>, are partial agonists at peroxisome proliferator-activated receptor-γ. | CPR:6 |
23487168.T1.T15 | Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly <C>telmisartan</C>, are partial agonists at <P>peroxisome proliferator-activated receptor-γ</P>. | CPR:5 |
23019138.T29.T17 | Direct-acting <P>CB1</P> agonists, including <C>Δ(9)-tetrahydrocannabinol</C>, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9β-(hydroxymethyl)-3-(1-ad... | CPR:5 |
23019138.T29.T18 | Direct-acting <P>CB1</P> agonists, including Δ(9)-tetrahydrocannabinol, <C>WIN 55,212</C> [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9β-(hydroxymethyl)-3-(1-ad... | CPR:5 |
23019138.T29.T19 | Direct-acting <P>CB1</P> agonists, including Δ(9)-tetrahydrocannabinol, WIN 55,212 [<C>R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate</C>], AM2389 [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9β-(hydroxymethyl)-3-(1-ad... | CPR:5 |
23019138.T29.T20 | Direct-acting <P>CB1</P> agonists, including Δ(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], <C>AM2389</C> [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [9β-(hydroxymethyl)-3-(1-ad... | CPR:5 |
23019138.T29.T21 | Direct-acting <P>CB1</P> agonists, including Δ(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [<C>9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol</C>], and AM4054 [9β-(hydroxymethyl)-3-(1-ad... | CPR:5 |
23019138.T29.T22 | Direct-acting <P>CB1</P> agonists, including Δ(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and <C>AM4054</C> [9β-(hydroxymethyl)-3-(1-ad... | CPR:5 |
23019138.T29.T23 | Direct-acting <P>CB1</P> agonists, including Δ(9)-tetrahydrocannabinol, WIN 55,212 [R-(1)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate], AM2389 [9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol], and AM4054 [<C>9β-(hydroxymethyl)-3-(1-adaman... | CPR:5 |
23019138.T4.T24 | <C>Methanandamide</C> (10.0 mg/kg) had lesser effect than other CB agonists, and the <P>CB2</P> agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects. | 0 |
23019138.T24.T5 | Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the <P>CB2</P> agonist <C>AM1241</C> [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects. | CPR:5 |
23019138.T24.T6 | Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the <P>CB2</P> agonist AM1241 [<C>1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole</C>], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects. | CPR:5 |
23019138.T24.T7 | Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the <P>CB2</P> agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the <C>anandamide</C> transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects. | 0 |
23019138.T24.T8 | Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the <P>CB2</P> agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor <C>AM404</C>, and the CB antagonist rimonabant did not have diuretic effects. | CPR:5 |
23019138.T24.T9 | Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the <P>CB2</P> agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist <C>rimonabant</C> did not have diuretic effects. | 0 |
23019138.T25.T10 | In further studies, the diuretic effects of the <P>CB1</P> agonist <C>AM4054</C> were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were... | CPR:5 |
23019138.T10.T26 | In further studies, the diuretic effects of the CB1 agonist <C>AM4054</C> were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the <P>vanilloid receptor type I</P> antagonist capsazepine, nor were... | 0 |
23019138.T10.T27 | In further studies, the diuretic effects of the CB1 agonist <C>AM4054</C> were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist capsazepine, nor were the ef... | 0 |
23019138.T25.T11 | In further studies, the diuretic effects of the <P>CB1</P> agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with <C>rimonabant</C>, but not by the vanilloid receptor type I antagonist capsazepine, nor were... | CPR:6 |
23019138.T11.T26 | In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with <C>rimonabant</C>, but not by the <P>vanilloid receptor type I</P> antagonist capsazepine, nor were... | 0 |
23019138.T11.T27 | In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with <C>rimonabant</C>, but not by the vanilloid receptor type I antagonist capsazepine, nor were the ef... | 0 |
23019138.T25.T12 | In further studies, the diuretic effects of the <P>CB1</P> agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the <C>vanilloid</C> receptor type I antagonist capsazepine, nor were... | 0 |
23019138.T12.T27 | In further studies, the diuretic effects of the CB1 agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the <C>vanilloid</C> receptor type I antagonist capsazepine, nor were the ef... | 0 |
23019138.T25.T13 | In further studies, the diuretic effects of the <P>CB1</P> agonist AM4054 were similar in male and female rats, displayed a relatively rapid onset to action, and were dose-dependently antagonized by 30 minutes pretreatment with rimonabant, but not by the vanilloid receptor type I antagonist <C>capsazepine</C>, nor were... | 0 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.